A new dawn for gemtuzumab ozogamicin?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.Pediatric blood & cancer · 2015
   Trial
2. Current status and research directions in acute myeloid leukemia.Blood cancer journal · 2024
   Review
3. Acute myeloid leukemia: current progress and future directions.Blood cancer journal · 2021
   Review
4. The Analysis of Key Factors Related to ADCs Structural Design.Frontiers in pharmacology · 2019
   Review
5. Update on antigen-specific immunotherapy of acute myeloid leukemia.Current hematologic malignancy reports · 2015
   Review

Corrections and comments

• Comment on
  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as